NASDAQ · LFMD
Healthcare · Medical - Pharmaceuticals
$3.03
Up+$0.08 (+2.54%)
Updated Sep 11, 2026, 5:33 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
LFMD closed at $3.03 after 20 trading sessions, down 12.43% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $2.91 | $3.065 | $2.91 | $3.03 | 1.03M |
| Sep 9, 2026 | $3.11 | $3.11 | $2.93 | $2.955 | 1.1M |
| Sep 8, 2026 | $3.06 | $3.15 | $3.04 | $3.09 | 940.91K |
| Sep 4, 2026 | $3.03 | $3.10 | $3.02 | $3.08 | 605.07K |
| Sep 3, 2026 | $3.11 | $3.145 | $3.025 | $3.05 | 578.8K |
| Sep 2, 2026 | $3.07 | $3.1225 | $3.03 | $3.07 | 731.01K |
| Sep 1, 2026 | $3.09 | $3.23 | $3.0539 | $3.10 | 748.95K |
| Aug 31, 2026 | $3.20 | $3.28 | $3.08 | $3.09 | 697.28K |
| Aug 28, 2026 | $3.26 | $3.30 | $3.14 | $3.14 | 466.44K |
| Aug 27, 2026 | $3.25 | $3.31 | $3.215 | $3.26 | 385.48K |
| Aug 26, 2026 | $3.22 | $3.295 | $3.20 | $3.24 | 476.32K |
| Aug 25, 2026 | $3.14 | $3.265 | $3.13 | $3.25 | 524.42K |
| Aug 24, 2026 | $3.28 | $3.31 | $3.12 | $3.14 | 411.49K |
| Aug 21, 2026 | $3.29 | $3.3399 | $3.24 | $3.31 | 406.48K |
| Aug 20, 2026 | $3.36 | $3.41 | $3.28 | $3.28 | 390.8K |
| Aug 19, 2026 | $3.33 | $3.44 | $3.28 | $3.40 | 544.46K |
| Aug 18, 2026 | $3.28 | $3.355 | $3.24 | $3.27 | 658.13K |
| Aug 17, 2026 | $3.41 | $3.48 | $3.305 | $3.32 | 513.83K |
| Aug 14, 2026 | $3.45 | $3.485 | $3.365 | $3.45 | 680.13K |
| Aug 13, 2026 | $3.30 | $3.48 | $3.27 | $3.46 | 748.39K |
The latest Smart Investors Daily articles mentioning LFMD.
LFMD research
Company profile and research snapshot.
LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | B. Riley Securities | Buy | — |
| Aug 6, 2026 | BTIG | Buy | — |
| May 26, 2026 | HC Wainwright & Co. | Buy | — |
| May 4, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 1, 2026
https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
SeekingAlpha · Aug 20, 2026
LifeMD trades at a historically low 0.75x TTM revenue multiple amid a 48% one-year share price decline.
SeekingAlpha · Aug 11, 2026
2026-08-11. The following slide deck was published by LifeMD, Inc.
Benzinga · Aug 7, 2026
HC Wainwright & Co. analyst Yi Chen maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $10 to $9.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LFMD.
